CASC2 and lobular neoplasia: Supporting this, ROC analysis revealed lncRNA CASC2 as a promising diagnostic biomarker that could differentiate between non-LN and control groups with a 96.67% sensitivity and 100% specificity, also as a sensitive predictor to LN disease due to its ability to discriminate between LN and non-LN groups with an 86.67% sensitivity and 66.7% specificity.